DMA (Diabetes Mellitus & Microbiota Associations)

Introduction

Heterogeneity in host and gut microbiota hampers microbial precision intervention of type 2 diabetes mellitus (T2DM). In our research, we recognized an important clinical parameter, stool type, for the stratification of patients with T2DM using machine learning and statistical approaches. Using the multiomics profiles, we found that, compared to patients with long-lasting dry stools (DM-DS), patients with long-lasting loose stools (DM-LS) exhibited discordant gut microbial taxonomic and functional profiles, severe host metabolic disorder, and excessive insulin secretion.

The host-microbe associations were also heterogeneous between the T2DM subgroups. Cross-measurement-association-analysis linked the differential microbial profiles, in particular Blautia abundances, to T2DM phenotypes in our stratified multi-omics dataset. In our recently published work, we conducted oral supplementation of Blautia to T2DM mice and observed the induced inhibitory effects on lipid accumulation, weight gain, and blood-glucose elevation with simultaneous modulation of gut bacterial composition. We reported the therapeutic potential of Blautia and recognized it as a bacterial modulator for microbial precision treatment of T2DM.

As host-microbe associations inferred by cross-measurement association analyses are important clues for bacterial treatment for diseases, we reinforce the importance of considering the heterogeneous associations caused by the heterogeneities within the multiomics features of the patient population. Here, we present all the direct and indirect correlations we detected in the T2DM subgroups in our online database, DMA (Diabetes Mellitus & Microbiota Associations). We call for further animal experiments to verify our findings and collaborations to promote the microbial precision medicine of T2DM.

Figure 1. Overview of the study design. (A) Summary of enrollment, screening and multiomics data detection of a human T2DM cohort with stable loose or dry stools. (B) The workflow of a mouse intervention study with oral administration of Blautia.

Datasets download

1.alldirect_spearman_cor.txt

2.path_from_microbiota_to_cellfactor.txt

Citation

Qian Guo, Zezheng Gao, Linhua Zhao, Han Wang, Zhen Luo, Doris Vandeputte, Lisha He, Mo Li, Sha Di, Yanwen Liu, Jiaheng Hou, Xiaoqing Jiang, Huaiqiu Zhu, Xiaolin Tong; Multi-omics analyses with stool-type stratification in patient cohorts and Blautia identification as a potential bacterial modulator in T2DM. Diabetes 2023; db230447. https://doi.org/10.2337/db23-0447

Latest update on December 19th, 2023